You are here

Clinical Trials: Cord Blood

Comment

Discuss
Conditions:   Severe Aplastic Anemia;   Hypo-Plastic MDS;   Myelodysplastic Syndrome (MDS)
Intervention:   Biological: CordIn(TM)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 18, 2017
Condition:   Alzheimer's Disease
Interventions:   Biological: human umbilical cord blood derived mesenchymal stem cells;   Other: Normal saline 2mL
Sponsor:   Medipost Co Ltd.
Recruiting - verified May 2017
Condition:   Acute Graft Versus Host Disease
Intervention:   Biological: MSCTC-0010 Dose Escalation
Sponsor:   Joseph McGuirk
Not yet recruiting - verified May 2017
Conditions:   Cerebral Palsy;   Child Development
Intervention:   Biological: allogeneic cord blood transplantation
Sponsor:   Bundang CHA Hospital
Recruiting - verified April 2017
Condition:   Hematologic Disorders
Intervention:   Device: Miltenyi CliniMACS® CD34 Reagent System
Sponsor:   University of Colorado, Denver
Not yet recruiting - verified March 2017
Condition:   Hematopoietic/Lymphoid Cancer
Interventions:   Drug: Busulfan;   Drug: Rituximab;   Drug: ATG;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation;   Procedure: Cord Blood Transplant;   Drug: Mycofenolate mofetil;   Drug: Tacrolimus;   Drug: G-CSF;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Mesna
Sponsors:   M.D. Anderson Cancer Center;   Mesoblast, Inc.
Not yet recruiting - verified March 2017
Condition:   Cerebral Palsy
Intervention:   Biological: Matched sibling donor cord blood cell infusion
Sponsors:   Murdoch Childrens Research Institute;   The Royal Children's Hospital Melbourne;   Children's Health Queensland;   Monash Health;   Sydney Children's Network;   Cerebral Palsy Alliance
Recruiting - verified March 2017
Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
Sponsor:   Loyola University
Recruiting - verified March 2017
Conditions:   B-Lymphoid Malignancies;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Non-hodgkin Lymphoma
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells;   Drug: AP1903
Sponsors:   M.D. Anderson Cancer Center;   Bellicum Pharmaceuticals
Not yet recruiting - verified April 2017
Condition:   B-Cell Non-Hodgkin Lymphoma
Interventions:   Biological: NK Cells;   Drug: Rituximab;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Lenalidomide 10Mg Capsule;   Drug: G-CSF;   Biological: Auto SCT;   Other: Apheresis
Sponsor:   M.D. Anderson Cancer Center
Not yet recruiting - verified March 2017
Conditions:   Stroke;   Stroke, Acute;   Brain Injury, Acute
Interventions:   Biological: Umbilical Cord Blood;   Other: Placebo
Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation;   Emory University;   M.D. Anderson Cancer Center
Recruiting - verified March 2017
Condition:   Cell Transplantation
Interventions:   Drug: Pneumostem;   Drug: Normal saline
Sponsor:   Samsung Medical Center
Recruiting - verified April 2017
Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: NiCord®;   Other: Cord Blood Unit
Sponsor:   Gamida Cell ltd
Recruiting - verified December 2016
Condition:   Inherited Metabolic Disorders (IMD)
Intervention:   Drug: Umbilical cord blood transplantation with HSC835
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2017

Pages